EXAS data disappoints analysts - highlights differences with GeneNews test
....The study results also highlight differences with GeneNews’ (TSX:GEN) ColonSentry blood test designed to assess an individual’s current risk for colorectal cancer. The ColonSentry test has been approved by the New York state department of health, the most stringent level of review for a clinical lab service in the US, and is commercially available through distributors and marketing partners in the US, Canada, Malaysia and China.
“As a risk-stratification test providing information about an individual’s current risk of having colorectal cancer, ColonSentry may facilitate a decision to undergo colonoscopy for those who would otherwise refuse the procedure,” GeneNews president and COO Gailina Liew said recently.
ColonSentry is the world’s first blood test to assess an individual’s current risk for colorectal cancer
“Importantly, it can also help prioritize patients at greater current risk for colorectal cancer in healthcare systems with limited colonoscopy capacity. Widespread adoption of the test could lead to earlier detection of colorectal cancer, improved patient outcomes and reduced healthcare costs.”
Exact’s Cologuard, which is not yet on the market, is attempting to be a potential replacement for colonoscopy and involves a patient handling their own stool. ColonSentry, on the other hand, is a risk-stratification test that requires only a small sample of blood and can be easily incorporated as a pre-screening measure into routine yearly physical exams.....